TradingMenu expanded
Forge Markets Forge Pro Browse Companies
DataMenu expanded
Forge Data Private Market Index Forge Accuidity Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News Tech IPO Calendar for 2024
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Forge Pro
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
Forge Accuidity Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
Tech IPO Calendar for 2024
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / Recursion Pharmaceuticals Stock

Recursion Pharmaceuticals Stock

recursionpharma.comHealthcare / BioTech & PharmaFounded: 2013Funding to Date: $333.7MM

Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering to industrialize drug discovery.

Buy or sell Recursion Pharmaceuticals stockLearn more about Recursion Pharmaceuticals IPO

Register To Buy and Sell Shares

For more details on financing and valuation for Recursion Pharmaceuticals, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Recursion Pharmaceuticals’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Recursion Pharmaceuticals.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Mason Victors
Chief Technology Officer & Chief Product Officer
Sharath Hegde
Chief Scientific Officer
Ronald Alfa Ph.D
Senior Vice President of Translational Discovery & Chief Evangelist
Blake Borgeson Ph.D
Co-Founder, Scientific Advisor & Board Member
Christopher Gibson Ph.D
Co-Founder, Chief Executive Officer & Board Member
Kevin Leggat
Controller
Kevin Lynch Ph.D
Chief Business Officer
Dean Li Ph.D
Board Member & Founder
Tina Larson
Chief Operating Officer
Ben Sukow
Director, Engineering
Heather Kirkby
Chief People Officer

Board Members

Blake Borgeson Ph.D
Zavain Dar
Lux Capital Management
Alaa Halawa
Mubadala Investment Company
Dean Li Ph.D
Zachary Bogue JD
Data Collective
Nan Li
Obvious Ventures
Christopher Gibson Ph.D
Reid Hutchins
Advantage Capital (Saint Louis)
Perry Fell Ph.D
James Hardiman
Data Collective

Frequently Asked Questions About Recursion Pharmaceuticals’ Stock

plusminus
Can you buy Recursion Pharmaceuticals’ stock?
Recursion Pharmaceuticals is not publicly traded on NYSE or NASDAQ in the U.S. To buy Recursion Pharmaceuticals’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Recursion Pharmaceuticals’ stock?
Yes, you can sell stock of a private company like Recursion Pharmaceuticals. Forge can help you sell your Recursion Pharmaceuticals stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Recursion Pharmaceuticals’ stock price?
Recursion Pharmaceuticals is a privately held company and therefore does not have a public stock price. However, you may access Recursion Pharmaceuticals’ private market stock price with Forge Data.
plusminus
What is Recursion Pharmaceuticals’ stock ticker symbol?
Recursion Pharmaceuticals does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Other companies like Recursion Pharmaceuticals in the BioTech & Pharma sector

Egenesis

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$387.57MM

Colossal Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B

Prime Medicine

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.23B

ADARx Pharmaceuticals

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$827.77MM

Altos Labs

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$6.33B

Tempus

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$8.7B

Pendulum Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$308.05MM

Cytonics

Sector
Healthcare / BioTech & Pharma
 
 

AI Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$110MM

News Highlights

Crunchbase 09/09/2020
Recursion Gets Funding For New Drug Discovery With Bayer-led $239M Series D
The new investment provides Recursion with capital to further develop its drug discovery platform and pipeline.
MarketScreener 07/31/2019
Recursion : Appoints Heather Kirkby as Chief People Officer

Trending Companies

Frequently Asked Questions

Updated on: Apr 25, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.